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'P' K 506 is a macrolide isolated from the cultures of the 
, fungus Streptomyces tsukubaensis.' It is nearly 200 
, times more potent than cyclosporine (CyA) in inhibiting 
lymphocyte proliferation in mixed lymphocyte cultures.2 
FK 506 has been shown to prevent or reverse the rejection 
/t, of heart. liver. kidney. pancreas. lung, intestine. and skin 
,:- grafts in mice. rats, dogs, monkeys, and baboons.3.4 FK 
.-; 506 is ,currently undergoing clinical trials at the University J of Pittsburgh. Preliminary results indicate that FK 506 
provides better immunosuppression in liver transplant 
•. recipients than CyA.s 
K1t~-
Previous in vitro and in vivo studies have shown syner-
gism of immunosuppressive activity between FK 506 and 
CyA.2.6 Coadministration of FK 506 with CyA has also 
been shown to result in increased nephrotoxicity in ani-
mals and humans. 7 .8 The mechanism of such an interaction 
is currently not understood. Such interaction may be 
" mediated through an influence of FK 506 on the absorp-
D~ tion, distribution, or elimination of Cy A. The objective of t the present study was to characterize the mechanism 
·-iii< responsible for the observed interaction between Cy A and 
K~ FK 506 in an animal model. 
·if", 
IK METHODS D~ 
q~ 
~D 
'.-;. 
Six male mongrel dogs weighing 12.8 to IS kg (mean 13.8 kg) were 
used in this study. Animals were fasted overnight before each 
study day and food was allowed 4 hours after drug administration. 
On day I, the animals received a single IV dose of 40 mg Cy A as 
a short I-minute infusion. Blood samples were collected in hep-
arinized vacutainers at 0.0.25.0.5. I, 1.5.2.4.6,8, 12,24, and 32 
hours after dosing. On day 5, the animals received an oral dose of 
ISO mg CyA in the form of the commercial oral solution, and 
samples were collected at 0, 0.25. 0.5, t, 2,3,4,6, 8, 12, 16,24, 
and 32 hours after dosing. On days 7 through 28, the dogs received 
a single oral dose of 2 mglkg per day of FK 506 (solid dispersion 
in a hard gelatin capsule). The IV CyA study was repeated on days 
8 and 22, and the oral study was repeated on day 28. Blood CyA 
was measured by HPLC.9 
Pharmacokinetic parameters of CyA were estimated from the 
data using standard model-independent analysis. 1O bne-way 
ANOV A was used to test for statistical significance of the 
differences in various parameters in different treatment groups 
after the IV studies and a two-tailed. paired t test was used to 
compare the oral data. The differences were considered significant 
if P $ .05. 
RESULTS 
The plasma concentration-time profiles following IV and 
oral Cy A in one of the dogs, before and after FK 506 
administration, are illustrated in Figs I and 2. The various 
pharmacokinetic parameters of Cy A in dogs before and 
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Fig 1. Blood CyA concentration versus time profile in one dog (IV 
dose of 40 mg as a bolus) before (e), after acute (A), and after 
chronic (_) treatment with FK 506. 
after acute or chronic administration of FK 506 are sum-
marized in Table 1. 
In all the animals. there were no significant differences 
among the three IV profiles. whereas the oral profiles 
differed considerably. The total body clearance, TBC. was 
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Fig 2. Blood CyA concentration versus time profile in one dog 
(PO dose of 150 mg) before (e) and after chronic (A) treatment 
with FK 506. 
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Table 1. Influence of FK 506 on CyA Kinetics In Dogs. 
Parameters Control Acute Chronic Significance t 
(h-') 0.102 j; 0.047 0.141 :!:0.116 0.087 j; 0.031 NS 
NS 
NS 
NS 
NS 
NS 
NS 
.01 
.005 
',/2 (h) 
MRT (h) 
8.89 j; 5.75 7.07 j; 3.64 9.08 j; 4.27 
9.40 j; 3.24 7.37 j; 3.65 9.73 j; 3.74 
TBe (mUmin/kg) 
V .. (Ukg) 
4.61 j; 1.31 5.13j;1.54 4.48 j; 1.47 
2.32 j; 0.63 2.01 j; 0.61 2.39:t 0.20 
V"",. (Ukg) 2.95 j; 1.34 2.77 j; 0.91 3.16 j; 0.44 
V, (Ukg) 0.75 j; 0.40 0.69 j; 0.26 0.69 ± 0.30 
em.,. (nglmL) 
Fraction absorbed 
'Mean:t: SO. 
746 ± 109 
0.111 j; 0.023 
1488 ± 293 
0.401 ± 0.058 
tlV data compared using one-way ANOVA; oral dala using a two-tailed paired tlest. 
4.6 ± 1.31, 5.13 ± 1.54, and 4.48 ± 1.47 mUmin per 
kilogram on days I, 8, and 22, respectively. The terminal 
disposition half-life after IV administration was 8.89 ± 
5.75,7.07 ± 3.64, and 9.08 ± 4.27 hours. The steady-state 
volume of distribution was 2.32 ± 0.63, 2.01 ± 0.61. and 
2.39 ± 0.61 and 2.39 ± 0.20 Llkg. None of the parameters 
calculated from IV data differed significantly among treat-
ments. On the other hand, the fraction of the oral dose of 
Cy A that was absorbed increased significantly from 11.1 ± 
2.3% before FK 506 treatment to 40.1 ± 5.8% after chronic 
dosing with FK 506. The observed maximum blood Cy A 
concentration also increased significantly from 746 ± 109 
to 1488 ± 293 ng/mL (Table 1). 
DISCUSSION 
Combination of multiple immunosuppressive drugs are 
often used to maximize the immunosuppressive efficacy 
~a~ to minimize the potential side effects. Preliminary 
R::sults indicated increased nephrotoxicity and increased 
disposition half-life of Cy A (based on whole blood TDX) in 
patients treated with FK 506. FK 506 has been shown to 
impair hepatic drug metabolism in rats. 11.12 In vitro studies 
also indicate FK 506 to be an inhibitor of Cy A metabo-
lism. 13 The present study was designed to investigate the 
effect of FK 506 pretreatment on the kinetics of CyA. 
Reasonable size. permitting frequent blood sampling, as 
well as Similarity of GI physiology to man. prompted the 
choice of dogs as the animal model for the present study. 
In the present study, pretreatment with FK 506 did not 
produce any significant change in the clearance or volume 
of distribution of Cy A. This indicates that, at the doses 
used, FK 506 did not alter hepatic drug metabolism in the 
dogs. The dose of FK 506 selected for this study has been 
shown to be immunosuppressive in previous studies. A 
single oral dose of 1 mg/kg of FK 506 in mongrel dogs 
results in a mean (SD) peak plasma concentration of 2.9 ± 
1.2 nglmL in a mean time of 1.4 hours.14 The dose of 2 
mglkg used in this study is expected to provide a peak 
concentration of approximately 6 ngimL. At this concen-
tration. FK 506 appears to have no effect on the hepatic 
drug metabolizing enzyme activity. 
On the other hand. pretreatment of dogs with 2 mglkg of 
FK 506 orally for 21 days produced a dramatic fourfold 
increase in the mean oral bioavailability of Cy A. There is 
evidence to suggest that CyA undergoes intestinal first-
pass elimination. 15 Inhibition of intestinal first-pass elimi-
nation of Cy A by FK 506 appears to explain, at least in 
part, the enhancement of CyA bioavailability in dogs. 
Erythromycin, another macrolide, appears to enhance 
Cy A blood concentrations by a similar mechanism. 16 
Erythromycin is an inhibitor of cytochrome P-450IIIc, the 
enzyme responsible for CyA metabolism. 17 FK 506. per-
haps, inhibits this enzyme in the intestinal tract, since it is 
present at this site at a fairly high concentration. A 
physical interaction between Cy A and FK 506 is not likely, 
since CyA was administered 1 hour after the FK 506 dose. 
It is possible that FK 506 may alter intestinal permeability 
of CyA, even though there is no experimental evidence to 
support this hypothesis. FK 506 does not interfere with the 
HPLC analysis of Cy A. 
It may be inferred from the results of the present study 
that FK 506 pretreatment results in an enhancement of 
CyA absorption: therefore. caution should be exercised 
when patients receiving FK 506 are switched to CyA. 
Furthermore. if combined therapy of CyA and FK 506 is 
recommended. the dose of Cy A should be reduced more 
than proportionately to compensate for the enhanced 
absorption. and guard against the development of toxicity. 
CONCLUSIONS 
Pretreatment with FK 506 for up to 21 days did not appear 
to alter the distribution or elimination characteristics of 
Cy A in dogs. On the other hand, a significant increase in 
the fraction of Cy A absorbed was observed after FK 506 
pretreatment for 21 days. possibly due to inhibition of 
intestinal first-pass metabolism. 
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